resmed inc (RMD) Key Developments
ResMed Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 03:20 PM
Jun 8 15
ResMed Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 03:20 PM. Venue: Four Seasons Hotel, Chicago, Illinois, United States.
ResMed Inc. Opens New Atlanta Distribution Center
Jun 5 15
ResMed Inc. announced the opening of new Atlanta distribution center in this week, which is nearly half a million square foot distribution center, with a very, very nicely semi-automated material handling system that will guarantee excellent performance on delivery of orders to customers.
ResMed Inc. - Analyst/Investor Day
May 29 15
ResMed Inc. - Analyst/Investor Day
ResMed Unveils Lumis Series of Noninvasive Ventilation Devices
May 20 15
ResMed Inc. has unveiled the Lumis series of noninvasive ventilation devices with wireless connected care capabilities. The Lumis series builds upon ResMed's legacy of innovation as a new option for patients with respiratory challenges who are not dependent on continuous ventilation. The Lumis series comprises the Lumis 100 VPAP S, Lumis 100 VPAP ST and Lumis 150 VPAP ST noninvasive ventilators that support a variety of therapy modes, built-in wireless connectivity, integrated humidification and intuitive simplicity that are the hallmarks of the series. Lumis is the first ResMed ventilation platform with IntelligentAir, a collection of ResMed technologies that can tailor therapy to individual breathing needs, making truly personalized ventilation possible. The complete IntelligentAir suite for Lumis includes iVAPS (ResMed's unique volume-assurance therapy mode), iBR (an intelligent Backup Rate), and AutoEPAP (which maintains upper airway patency), as well as other features to personalize and fine-tune individual patient's synchrony and comfort (Vsync, TiControl, and trigger and cycle settings). Lumis's each device features built-in HumidAir heated humidification capabilities and the popular Climate Control Auto setting, which automatically determines optimal humidification by adjusting to ambient room conditions. Lumis is compatible with ClimateLineAir Oxy tubing that allows for added oxygen to be heated and humidified, which is useful for patients with chronic obstructive pulmonary disease. In addition, the Lumis optional Ramp and Ramp Down features can ease the transition onto ventilation and back to spontaneous breathing when therapy is complete. The Lumis series was designed with connected care capabilities that can improve overall patient care and streamline patient monitoring and therapy management. Lumis' built-in wireless connectivity means that clinicians and home medical equipment providers have next-day access to a wide range of their patients' therapy parameters, including blood oxygen saturation when an oximeter is attached. These data, along with therapy statistics and trend data useful for home titration and monitoring, are automatically and securely transmitted to AirView, ResMed's cloud-based patient management system. AirView also includes a popular Remote Assist feature that providers can use to troubleshoot common therapy questions and change therapy settings remotely. Lumis devices are designed for simplicity and ease-of-use right out of the box. Every device comes built for quick setup thanks to an easy-to-read color screen, improved menu format, and simple push-dial navigation. Lumis' QuickNav feature also allows for easy toggling between the settings and monitoring screens to make it easy to see the real-time impact of configuration changes.
ResMed Inc. Provides Update on Phase III SERVE-HF Study of Adaptive Servo-Ventilation (Asv) Therapy
May 13 15
ResMed Inc. announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep apnea with Adaptive Servo-Ventilation (ASV) therapy could reduce mortality and morbidity in patients with symptomatic chronic heart failure in addition to optimized medical care. The study did not show a statistically significant difference between patients randomized to ASV therapy and those in the control group in the primary endpoint of time to all-cause mortality or unplanned hospitalization for worsening heart failure (based on a hazard ratio [HR] = 1.136, 95% confidence interval [95% CI] = (0.974, 1.325), p-value = 0.104). A preliminary analysis of the data identified a statistically significant 2.5% absolute increased risk of cardiovascular mortality for those patients in the trial who received ASV therapy per year compared to those in the control group. In the study, the cardiovascular mortality rate in the ASV group was 10% per year compared to 7.5% per year in the control group. There were no issues associated with the performance of the ASV therapy device in the trial.